New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells

Imatinib mesylate (IM, formerly STI571 or Glevec), a tyrosine kinase (TK) inhibitor which selectively targets ATP-binding sites of ABL and BCR-ABL proteins, is the frontline treatment of chronic myeloid leukemia (CML). The major caveat of IM therapy in CML is the development of secondary resistance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2010-12, Vol.28 (6), p.876-878
Hauptverfasser:	Santucci, Maria Alessandra, Mancini, Manuela, Corradi, Valentina, lacobucci, Ilaria, Martinelli, Giovanni, Botta, Maurizio, Schenone, Silvia
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Substitution - genetics Antigens, CD34 - metabolism Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Binding sites Bone marrow Chromatography Drug dosages Fusion Proteins, bcr-abl - antagonists & inhibitors Fusion Proteins, bcr-abl - metabolism Humans Inhibitor drugs Kinases Lethal Dose 50 Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology Medicine Medicine & Public Health Mutation Mutation - genetics Oncology Pharmacology Pharmacology/Toxicology Polymerase chain reaction Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Short Report Software src-Family Kinases - antagonists & inhibitors src-Family Kinases - metabolism Tumor Stem Cell Assay
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!